表紙
市場調査レポート

網膜静脈閉塞症:パイプライン製品の分析

Retinal Vein Occlusion - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 192808
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
網膜静脈閉塞症:パイプライン製品の分析 Retinal Vein Occlusion - Pipeline Review, H1 2016
出版日: 2016年05月11日 ページ情報: 英文 86 Pages
概要

網膜静脈閉塞症は、網膜の静脈のいずれかが閉塞して血管が詰まって血液が流れなくなる病気です。網膜では、像が神経信号に変換されます。主な症状は、無痛性の突然の視力変化です。素因として、アテローム性動脈硬化症、黄斑浮腫、糖尿病、高血圧、高コレステロール、年齢などが挙げられます。

当レポートでは、網膜静脈閉塞症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

網膜静脈閉塞症の概要

治療薬の開発

  • パイプライン製品の概要

網膜静脈閉塞症:企業で開発中の治療薬

網膜静脈閉塞症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

網膜静脈閉塞症:企業で開発中の製品

網膜静脈閉塞症の治療薬開発に従事している企業

  • Aerpio Therapeutics, Inc.
  • Avalanche Biotechnologies, Inc.
  • EyeGate Pharmaceuticals, Inc.
  • Kala Pharmaceuticals, Inc.
  • Mabion SA
  • NicOx S.A.
  • Ohr Pharmaceutical Inc.
  • Precision Ocular Ltd
  • pSivida Corp.
  • ThromboGenics NV

網膜静脈閉塞症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

網膜静脈閉塞症:最近のパイプライン動向

網膜静脈閉塞症:休止中のプロジェクト

網膜静脈閉塞症:開発が中止された製品

網膜静脈閉塞症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8050IDB

Summary

Global Markets Direct's, 'Retinal Vein Occlusion - Pipeline Review, H1 2016', provides an overview of the Retinal Vein Occlusion pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion
  • The report reviews pipeline therapeutics for Retinal Vein Occlusion by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Retinal Vein Occlusion therapeutics and enlists all their major and minor projects
  • The report assesses Retinal Vein Occlusion therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinal Vein Occlusion Overview
  • Therapeutics Development
    • Pipeline Products for Retinal Vein Occlusion - Overview
  • Retinal Vein Occlusion - Therapeutics under Development by Companies
  • Retinal Vein Occlusion - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Retinal Vein Occlusion - Products under Development by Companies
  • Retinal Vein Occlusion - Companies Involved in Therapeutics Development
    • Aerpio Therapeutics, Inc.
    • Avalanche Biotechnologies, Inc.
    • EyeGate Pharmaceuticals, Inc.
    • Kala Pharmaceuticals, Inc.
    • Mabion SA
    • NicOx S.A.
    • Ohr Pharmaceutical Inc.
    • Precision Ocular Ltd
    • pSivida Corp.
    • ThromboGenics NV
  • Retinal Vein Occlusion - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AKB-9778 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AVA-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dexamethasone acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs for Retinal Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fluocinolone acetonide SR - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • loteprednol etabonate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NCX-422 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NCX-434 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ocriplasmin (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • squalamine lactate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Retinal Vein Occlusion - Recent Pipeline Updates
  • Retinal Vein Occlusion - Dormant Projects
  • Retinal Vein Occlusion - Discontinued Products
  • Retinal Vein Occlusion - Product Development Milestones
    • Featured News & Press Releases
      • Nov 04, 2015: Alimera Sciences announces late breaking presentation of new ILUVIEN Analysis During Retina Subspecialty day at AAO annual meeting 2015
      • Sep 28, 2015: Alimera Sciences Announces Availability Of Review Paper On Real World Experience With ILUVIEN
      • Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion
      • Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion
      • Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
      • Jul 31, 2014: Kala Pharmaceuticals Initiates Phase 2 Clinical Trial to Evaluate LE-MPP (KPI-121) in Patients with Retinal Vein Occlusion and Diabetic Macular Edema
      • Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion
      • Dec 26, 2010: Alimera To Hold Conference Call To Discuss Complete Response Letter Regarding NDA For ILUVIEN
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Retinal Vein Occlusion, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Retinal Vein Occlusion - Pipeline by Aerpio Therapeutics, Inc., H1 2016
  • Retinal Vein Occlusion - Pipeline by Avalanche Biotechnologies, Inc., H1 2016
  • Retinal Vein Occlusion - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2016
  • Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals, Inc., H1 2016
  • Retinal Vein Occlusion - Pipeline by Mabion SA, H1 2016
  • Retinal Vein Occlusion - Pipeline by NicOx S.A., H1 2016
  • Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc., H1 2016
  • Retinal Vein Occlusion - Pipeline by Precision Ocular Ltd, H1 2016
  • Retinal Vein Occlusion - Pipeline by pSivida Corp., H1 2016
  • Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Retinal Vein Occlusion Therapeutics - Recent Pipeline Updates, H1 2016
  • Retinal Vein Occlusion - Dormant Projects, H1 2016
  • Retinal Vein Occlusion - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Retinal Vein Occlusion, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top